MINNEAPOLIS, September 16, 2024--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Steve Tipler as a managing director in the ...
JMP Securities analyst Devin Ryan maintained a Hold rating on Piper Sandler (PIPR – Research Report) today. The company’s shares closed yesterday at $271.44. According to TipRanks, Ryan is a ...
Piper Sandler has maintained a Neutral rating and an $8.00 price target for Hain Celestial (NASDAQ: NASDAQ:HAIN), following the divestiture of its ParmCrisp business. The firm has adjusted its ...
Investing.com -- Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per share. Piper Sandler emphasizes Abbott’s ...
Piper Sandler has maintained a positive outlook on Immunic Inc. (NASDAQ: NASDAQ:IMUX), reiterating an Overweight rating with a price target of $28.00. The firm's stance is based on the potential ...
Piper Sandler has sustained its Overweight rating and $26.00 price target for Zura Bio Ltd. (NASDAQ: ZURA), following a successful investor event in New York City. The firm highlighted the ...
Piper Sandler has reaffirmed its confidence in cybersecurity firm CrowdStrike Holdings (NASDAQ: NASDAQ:CRWD), maintaining an Overweight rating and a price target of $290.00 on the company's stock.
Piper Sandler analyst Adam Maeder maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target of $71.00. The company’s shares closed ...
Piper Sandler has reaffirmed its Overweight rating and $18.00 price target for Tango Therapeutics Inc. (NASDAQ: TNGX), following recent data presentations. Tango Therapeutics, a biotechnology ...
Piper Sandler has reaffirmed its Overweight rating on shares of Pliant Therapeutics (NASDAQ: PLRX), maintaining a $40.00 price target. The endorsement follows a recent announcement from Boehringer ...
Piper Sandler revealed in a research note that its latest survey shows most investors view bank stocks as undervalued and expect a positive outlook for the sector. In a survey of 574 bank investor ...
Piper Sandler has reaffirmed its positive stance on Nuvalent (NASDAQ: NUVL), maintaining an Overweight rating and a $100.00 price target. The endorsement follows the complete Phase 1 data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback